"10.1371_journal.pmed.0020333","plos medicine","2005-11-01T00:00:00Z","Matthew L Batten; Yoshikazu Imanishi; Daniel C Tu; Thuy Doan; Li Zhu; Jijing Pang; Lyudmila Glushakova; Alexander R Moise; Wolfgang Baehr; Russell N Van Gelder; William W Hauswirth; Fred Rieke; Krzysztof Palczewski","Department of Ophthalmology, University of Washington, Seattle, Washington, United States of America; Department of Pharmacology, Case School of Medicine, Case Western Reserve University, Cleveland, Ohio, United States of America; Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, United States of America; Department of Physiology and Biophysics, University of Washington, Seattle, Washington, United States of America; Department of Chemistry, University of Washington, Seattle, Washington, United States of America; Department of Ophthalmology, and Powell Gene Therapy Center, University of Florida, Gainesville, Florida, United States of America; Department of Ophthalmology, University of Utah, Salt Lake City, Utah, United States of America; Department of Biology, University of Utah, Salt Lake City, Utah, United States of America; Department of Neurobiology and Anatomy, University of Utah, Salt Lake City, Utah, United States of America; Department of Molecular Biology, Washington University School of Medicine, St. Louis, Missouri, United States of America; Department of Pharmacology, Washington University School of Medicine, St. Louis, Missouri, United States of America; Department of Pharmacology, University of Washington, Seattle, Washington, United States of America","MLB, YI, DCT, TD, LZ, JP, LG, ARM, WB, RNVG, WWH, FR, and KP contributed to conception and design, or acquisition of data, or analysis and interpretation of data. MLB, YI, DCT, TD, LZ, ARM, WB, RNVG, WWH, FR, and KP contributed to writing the paper.","WWH and the University of Florida own equity in a company, Applied Genetic Technologies Corporation, that may commercialize some of the technology described in this work. KP owns shares of the company Retinagenix. The University of Washington and Retinagenix may commercialize some of the technology described in this work.","2005","11","Matthew L Batten","MLB",13,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
